Letter

Discriminating invasive fungal infection from colonization

Stijn Blot^1,2,3 , Koenraad Vandewoude^2,3 and Dirk Vogelaers^1,3

¹  General Internal Medicine and Infectious Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium

²  Faculty of Healthcare, University College Ghent, Keramiekstraat 80, 9000 Ghent, Belgium

³  Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium

author email corresponding author email

Critical Care 2008, 12:412doi:10.1186/cc6835

Published:	3 April 2008

See related research by Xie et al., http://ccforum.com/content/12/1/r5

First paragraph (this article has no abstract)

We read with interest the article by Xie and colleagues reporting the impact of invasive fungal infection (IFI) on outcomes [1]. In a cohort of 318 intensive care unit patients with severe sepsis they found 90 patients with IFI (28.3%). Ninety-three per cent of the IFIs were caused by Candida species, 3% by Aspergillus species and 4% were unclassified. Predominant sites of infection were the lung (56.4%) and the abdomen (22.7%). As such, Candida pneumonia was the most frequent type of infection in this cohort, representing 53.6% of all IFIs (we assume that all cases of aspergillosis were pulmonary). This is most remarkable as the presence of Candida in respiratory tract cultures is seldom pathogenic and Candida pneumonia is considered a rare disease entity in which the diagnosis can only be made by histological confirmation [2]. The same remark is valid for intra-abdominal IFI. The presence of Candida from intraabdominal cultures does not necessarily represent Candida peritonitis [3].